Inhibrx Biosciences (INBX) Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Current Assets data on file, last reported at $132.8 million in Q4 2025.

• On a quarterly basis, Current Assets fell 17.19% year-over-year to $132.8 million in Q4 2025; TTM through Dec 2025 was $132.8 million, a 17.19% decrease from a year earlier, with the FY2025 full-year figure at $132.8 million, down 17.19% from the prior year.
• Current Assets for Q4 2025 stood at $132.8 million, down from $161.4 million in the prior quarter.
• Over the last five years, Current Assets for INBX reached as high as $295.4 million in Q4 2023 and fell as low as $132.8 million in Q4 2025.
• Historically, Current Assets has averaged $202.1 million across 3 years, with a median of $200.7 million in 2024.
• Across the five-year window, Current Assets plunged 45.69% in 2024 and dropped 17.19% in 2025, its largest moves.
• Year by year, Current Assets stood at $295.4 million in 2023, then plunged by 45.69% to $160.4 million in 2024, then fell by 17.19% to $132.8 million in 2025.
• Per Business Quant data, the three most recent Current Assets figures were $132.8 million in Q4 2025, $161.4 million in Q3 2025, and $194.0 million in Q2 2025.